• Теги
    • избранные теги
    • Компании2426
      • Показать ещё
      Разное641
      • Показать ещё
      Страны / Регионы375
      • Показать ещё
      Международные организации32
      • Показать ещё
      Люди131
      • Показать ещё
      Формат28
      Показатели62
      • Показать ещё
      Издания62
      • Показать ещё
      Сферы2
Выбор редакции
05 декабря, 19:30

A New Antibody For Treating Acute Lymphocytic Leukemia?

Of all the drugs being discussed at this year’s meeting of the American Society of Hematology, one caught my attention. The new agent, a monoclonal antibody to CD22 with a toxin attached, is manufactured by Pfizer. It’s called inotuzumab ozogamicin. As that’s a mouthful, some doctors call it Ino. Last summer [...]

05 декабря, 19:06

A Trump Nation in an ALEC land

The first post-presidential American Legislative Exchange Council (ALEC) meeting this week in Washington, DC made clear that starry-eyed conservative state legislators had visions of more power dancing in their heads. Corporations were giddy thinking about the tax giveaways and incentive packages (think the $7 million Trump/Pence tax giveaways to Carrier to keep less than one-half of its jobs in that state) surely coming their way. Even keynote speaker Carly Fiorina this morning seemed hopeful, seemingly forgetful of Trump's former abuse. Certainly, Trump wasn't the first choice of most ALEC members. Many other Republican presidential hopefuls had come to kiss the ALEC ring over the course of the Republican presidential primary. ALEC prince Scott Walker came before he fell off the presidential cliff. Kellyanne Conway appeared before ALEC in July, then a mere pollster. She (correctly) identified the mood of the electorate (very angry), and said that only a "change agent" like Trump could prevail. Even Mike Pence showed up to ALEC, but still no Trump. The ALEC audience was Trump wary. Times have changed. Conservative state legislators, right wing think tanks and corporate lobbyists, the three legs of the ALEC stool, understand that the collision of a Trump presidency in an ALEC country, where 33 states are now totally in Republican control, offers loads of possibilities to further advance corporate dominance and profits. Though several ALEC members borrowed Trump's "draining the swamp" reference to Washington DC, the alligators (i.e., corporate lobbyists) were swimming all around the ALEC conference, ready to take a deep dive into a swamp growing larger by the day. The Trump team is filling up on billionaires and political insiders, and that suites the ALEC crowd just fine. After all, ALEC exists to maximize the profits of their corporate kings, including Koch Industries, Exxon Mobile, PhrMA, Altria, and Pfizer, who pay upwards of $25,000 to become members. Left in the dust are the working low and middle income people of our country, who only get the crumbs of the trickle down, top down economic system that ALEC promotes and from which Trump has reaped a lifetime of rewards. The priorities of a Trump presidency and ALEC are identical - more tax cuts for the wealthy as the wages of low and middle income workers stagnate, gutting environmental protections and clean energy initiatives, and privatizing public education. At the Education and Workforce Taskforce meeting today, the next wave of K-12 privatization efforts were pushed in the form of Educational Savings Accounts (ESAs), where a portion of state monies spent on public education is given directly to parents to spend in any way or at any school they choose with little oversight. According to a director from the J. Stanley Marshall Center for Educational Options, even "horse therapy" can be covered by ESAs. My Wisconsin Republican colleagues, several of whom were present at the taskforce meeting today, recently indicated that they were considering ESAs for Wisconsin. This is on top of the unaccountable private voucher and charter schools siphoning approximately $500 million this biennium from Wisconsin's public schools, schools that are now receiving $1,000 less per pupil, adjusting for inflation, than they did in 2008. Betsy DeVos, another billionaire Trump appointee as Secretary of Education, has lead the charge in privatizing, and ultimately trying to destroy, public education. ALEC members are salivating at the prospects. As usual, the likely big losers in this collision of Trump nation with an ALEC land are actual people. But that is a sacrifice ALEC is always willing to make. -- This feed and its contents are the property of The Huffington Post, and use is subject to our terms. It may be used for personal consumption, but may not be distributed on a website.

Выбор редакции
05 декабря, 17:08

Pfizer (PFE) Presents Favorable Data on Leukemia Candidate

Pfizer Inc. (PFE) announced new positive data from a randomized phase II study on its investigational candidate glasdegib (PF-04449913) for the first-line treatment of patients with acute myeloid leukemia (AML).

05 декабря, 07:50

Тимур Ханнанов, «Татхимфармпрепараты»: «Многие законы у нас пишутся западными компаниями»

«В России мы покупаем только картофельный крахмал и сахар, все остальное на 90 - 95 процентов заграничное», — рассказывает гендиректор АО «Татхимфармпрепараты» Тимур Ханнанов о нынешнем состоянии отечественной фармотрасли. В интервью «БИЗНЕС Online» он рассказал, возрождается ли в России производство собственных лекарственных эссенций, а также как ему удалось выбраться из валютной ловушки, открыв абсолютно новое производство.

Выбор редакции
Выбор редакции
02 декабря, 17:52

Merck's Keytruda Gets Priority Review for Hodgkin Lymphoma

Merck & Co., Inc.'s (MRK) supplemental Biologics License Application (sBLA) ??? the second this week ??? for its anti-PD-1 therapy, Keytruda, has been accepted for priority review by the FDA.

02 декабря, 17:33

Pfizer Offers Positive Phase III Data on Pediatric Epilesy Drug

Pfizer Inc. (PFE) announced positive top-line results from a phase III study evaluating its marketed drug, Lyrica (pregabalin), as adjunctive therapy for the treatment of pediatric patients suffering from epilepsy with partial-onset seizures.

02 декабря, 16:42

Is American Century Large Company Value Investor Fund (ALVIX) Worth Another Look?

American Century Large Company Value Investor Fund (ALVIX) a Zacks Rank #2 (Buy) was incepted in October 2000 and is managed by American Century Investment Management, Inc

02 декабря, 15:01

Против людей начинают использовать "иммунокастрацию"

Письмо в редакцию:Здравствуйте. Я по профессии ветеринарный врач, являюсь вашим постоянным читателем и слежу за интересными и ужасными событиями в мире.Обращаюсь к вам с информацией, которой поделились со мной мои коллеги из Голландии. С 1 января 2018 года в странах ЕС вводят запрет на хирургическую кастрацию поросят, вместо этого вводят повсеместную "иммунокастрацию" препаратом Импровак пр-во Pfizer (Zoetis)-USA. Этот препарат описывают как вакцину, но по сути это очень опасный гормональный препарат, использование которого ведет к рассасыванию тестикул (семенников) у хрячков и яичников у свинок.Во время испытаний препарата в Бразилии отмечалось около 10 случаев самоинъекций обслуживающего персонала с возникновением соответствующей реакции у людей. Опасность применения препарата в том, что мясо, полученное от животных, кастрированных этим методом может вызвать бесплодие у людей (компания производитель отрицает вредное воздействие препарата на людей, но верить ей нельзя).Исходя из того, что есть категории людей не употребляющие свинину (иудеи и мусульмане), не сложно предположить против кого направлено сие оружие и какие глобальные последствия ожидают человечество в недалеком будущем.Эта методика также постепенно вводится на некоторых свиноводческих предприятиях Украины и не исключено что и России тоже.

02 декабря, 14:40

Pharma Stock Roundup: Nivalis Falls on Study Data, Priority Reviews for Merck's Keytruda

This week, companies like Merck (MRK) and Pfizer (PFE) provided updates on their pipelines.

02 декабря, 00:20

5 Top Performing Biotechnology Stocks of November

November was a great month for pharma/biotech stocks after a rather difficult year when the industry struggled with media and political focus on high drug prices.

01 декабря, 17:08

Pfizer's Herceptin Biosimilar Meets Primary Endpoint in Study

Pfizer, Inc. (PFE) recently announced that its experimental biosimilar of Roche Holding AG's (RHHBY) breast cancer drug - Herceptin - has reached the primary endpoint in a pivotal study.

Выбор редакции
01 декабря, 16:18

BRIEF-Pfizer Inc, IBM announced a collaboration that will utilize IBM watson for drug discovery

* Ibm and pfizer to accelerate immuno-oncology research with watson for drug discovery

01 декабря, 16:00

Pfizer Partners With IBM Watson To Advance Cancer Drug Discovery

IBM Watson Health and drug maker Pfizer have formed a relationship to accelerate drug discovery in “immuno-oncology” using the computer giant’s artificial intelligence system.

01 декабря, 15:43

Exciting News From Pfizer And IBM

The pairing of Pfizer and IBM Watson is changing the field of research. Forbes' Bruce Japsen speaks with IBM's Deborah DiSanzo about the company's exciting new venture.

30 ноября, 18:03

ARIAD's Leukemia Drug Iclusig Gets Full Approval in U.S.

ARIAD Pharmaceuticals, Inc. (ARIA) announced that the FDA has granted a full approval to its leukemia drug, Iclusig (ponatinib), following its successful completion of the commitments made on accelerated approval in Dec 2012.

Выбор редакции
30 ноября, 16:38

Pfizer/Merck KGaA: Priority Review for Cancer Drug Avelumab

Pfizer, Inc. (PFE) and German partner Merck KGaA (MKGAF) announced that the Biologics License Application for avelumab, has been accepted for priority review by the FDA.

30 ноября, 16:33

J&J (JNJ) Stands Tall in 2016: Reasons for Outperformance

Johnson & Johnson's (JNJ) share price is up 9.5% in the year-to-date period. This compares favorably with the 8.0% fall for the Zacks classified Large-Cap Pharma industry.

16 мая, 21:20

Pfizer купила Anacor за $5,2 млрд // Американская фармкомпания расширяет свой портфель препаратов

Американская фармкомпания Pfizer купила производителя лекарства от экземы Anacor Pharmaceuticals за $5,2 млрд. Пока разработанный Anacor препарат крисаборол не поступил в продажу и находится на рассмотрении регулятора, но впоследствии его продажи могут достигнуть $2 млрд в год. По мнению экспертов, нынешняя сделка станет не последней для Pfizer в ближайшее время.

20 февраля, 22:30

Google "спасла" от налогов более 10 млрд евро

Американскому IT-гиганту Google удалось увести от налогов почти 11 млрд евро выручки в 2014 г. Для этого компания воспользовалась схемой, которую прозвали "двойной ирландский голландский сэндвич".